COMMUNIQUÉS West-GlobeNewswire

IBEX Technologies Signs Definitive Agreement for Sale of the Company for $1.45 Cash Per Share
12/02/2024
MONTREAL, Feb. 12, 2024 (GLOBE NEWSWIRE) -- IBEX Technologies Inc. (“ IBEX ” or the “ Company ”) (TSX Venture: IBT) is pleased to announce that it has entered into a binding acquisition agreement dated February 9, 2024 [...]
TECHNOLOGIES IBEX SIGNE UNE ENTENTE DÉFINITIVE VISANT LA VENTE DE LA SOCIÉTÉ POUR UNE CONTREPARTIE AU COMPTANT DE 1,45 $ PAR ACTION
12/02/2024
MONTRÉAL, 12 févr. 2024 (GLOBE NEWSWIRE) -- Technologies IBEX inc. (« IBEX » ou la « Société ») (Bourse de croissance TSX : IBT) est heureuse d’annoncer qu’elle a conclu une entente d’acquisition contraignante datée du [...]
VitalHub Announces First Canadian Licensing Agreement of the Award-Winning Intouch with Health Queue Management & Patient Journey Optimization Platform with Newfoundland & Labrador Health Services
12/02/2024
TORONTO, Feb. 12, 2024 (GLOBE NEWSWIRE) -- VitalHub Corp. (the "Company" or "VitalHub") (TSX:VHI) (OTCQX:VHIBF) is pleased to announce the first Canadian customer for the Intouch with Health Queue Management & [...]
Organogenesis Holdings Inc. to Participate in the BTIG Snowbird MedTech, Digital Health, Life Science and Diagnostic Tools Conference
12/02/2024
CANTON, Mass., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of product solutions [...]
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701 for Treatment of Small Cell Neuroendocrine Prostate Cancer (SCNC)
12/02/2024
Designation for BXCL701 in combination with a checkpoint inhibitor (CPI) for treatment of patients with metastatic SCNC with progression on chemotherapy and no evidence of microsatellite instability BXCL701 is an [...]
Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons
12/02/2024
Bagsværd, Denmark, 12 February 2024 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance [...]
Allakos Announces Publication Highlighting AK006 Mast Cell Inhibition
12/02/2024
– Data provide insights on the signaling pathways involved with AK006 mast cell inhibition – – AK006 has a distinct mechanism of action that leads to broad inhibitory effects on mast cells – SAN CARLOS, Calif., Feb. 12 [...]
BioCryst to Report Fourth Quarter 2023 Financial Results on February 26
12/02/2024
RESEARCH TRIANGLE PARK, N.C., Feb. 12, 2024 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will report its fourth quarter 2023 financial results on Monday, February 26 [...]
Gritstone bio Announces Update to Comparative Phase 2b COVID-19 Clinical Trial
12/02/2024
EMERYVILLE, Calif., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Gritstone bio, Inc. (Nasdaq: GRTS), a clinical-stage biotechnology company working to develop the world’s most potent vaccines, today announced that it is now [...]
Optimi Health Congratulates Lykos Therapeutics on FDA Priority Review of New Drug Application And Releases MDMA Production Video
12/02/2024
Company shares behind-the-scenes look at its GMP MDMA encapsulation and production process VANCOUVER, British Columbia, Feb. 12, 2024 (GLOBE NEWSWIRE) -- Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“ [...]
PolyPid Announces Enrollment of the 100th Patient in the Ongoing SHIELD II Phase 3 Trial
12/02/2024
Approximately 40 Centers Currently Open Unblinded Interim Analysis to be Conducted Once Approximately 400 Patients Complete Their 30-Day Follow-up; Top-line Results Expected in Second Half of 2024 Recent Successful $16 [...]
InspireMD Appoints Principal Investigators for C-GUARDIANS II Clinical Trial of the SwitchGuard™ Neuroprotection System
12/02/2024
Development of SwitchGuard™ consistent with Company’s mission to uniquely support both Carotid Artery Stenting (CAS) and Transcarotid Artery Revascularization (TCAR) procedures with best-in-class carotid implant and [...]
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich’s Ataxia
12/02/2024
Nomlabofusp was generally well tolerated following repeated subcutaneous injections in patients in the 25 and 50 mg cohorts with no serious adverse events Dose dependent increases in frataxin levels were observed in [...]
MediWound Announces Positive Results in Head-to-Head Comparison of EscharEx® vs. SANTYL® within the ChronEx Phase II Randomized Controlled Study
12/02/2024
Results demonstrate superiority of EscharEx®, a bromelain-based gel vs. SANTYL®, a collagenase ointment, in wound debridement, promotion of granulation tissue, and time to wound closure in patients with chronic venous [...]
Immunovant Reports Financial Results and Provides Corporate Updates for the Quarter Ended December 31, 2023
12/02/2024
Immunovant plans to initiate 4-5 potentially registrational programs for IMVT-1402 over the next fiscal year Immunovant plans to initiate trials in 10 indications for IMVT-1402 over the next two fiscal years Initial [...]
ECO Animal Health Appoints Dr. Joachim Hasenmaier as Non-Executive Director
12/02/2024
12 February 2024 ECO Animal Health Group plc (“ECO” or the “Company”) Appointment of Dr. Joachim Hasenmaier as Non-Executive Director ECO Animal Health Group plc (AIM: EAH), a rapidly growing global animal health [...]
Report on transactions with ALK-Abelló A/S B-shares and associated securities by managerial staff
12/02/2024
ALK ( ALKB:DC / OMX: ALK B / AKBLF ): In accordance with article 19 in Regulation (EU) No 596/2014 of 16 April 2014 on market abuse (the Market Abuse Regulation), ALK-Abelló A/S shall report the following transactions [...]
PCI Biotech: Invitation to second half interim 2023 results presentation
12/02/2024
Oslo, Norway, 12 February 2024 - PCI Biotech (OSE: PCIB) invites to a webcast presentation of the company's second half 2023 interim report on Wednesday 14 February 2024, 08:30am – 09:30am CET (local time). The [...]
Ibogaine By David Dardashti Shares Biomedical Engineers Take on Holistic Treatment
11/02/2024
Mark Leslie Mitchelson, MD Praises Alternative Approach to Health and Wellness MIAMI, Feb. 11, 2024 (GLOBE NEWSWIRE) -- Ibogaine By David Dardashti and Doctor Mark Leslie Mitchelson offer insights behind ibogaine [...]

Pages